Reditus Laboratories
Reditus Laboratories
Reditus Laboratories

Press Releases

REDITUS LABORATORIES REPORTS DELTA VARIANT MUTATING QUICKLYAugust 20, 2021

PEKIN, IL – Reditus Laboratories in Pekin identified 361 additional cases of the B.1.617.2 variant – also known as the Delta variant – and its sub-variants during a sequencing run on Aug. 12. These encompassed 99% of the entire sequenced positives.

Reditus CEO Dr. Aaron Rossi said on Friday night “The Delta variant (B.1.617.2) is currently the most predominate SARS-CoV-2 circulating within the U.S. and are supported by these data within our testing area. However, we are also seeing a large number of Delta sub-variants with some only beginning to be mentioned elsewhere. Specifically, the AY.12 subvariant is not as common in U.S. circulation. However, within our testing population, AY.12 is nearly equivalent in prevalence as the original B.1.617.2. These data suggest that the Delta variant is mutating as quickly as it has risen to the predominate strain.”

Reditus had reported one case of the Delta variant discovered via sequencing in May, two cases in June, 64 on July 16 and 347 on July 29. This means that Reditus has identified 775 cases of the Delta variant.

The majority of the 361 cases identified during the sequencing run on Aug. 12 were from people from throughout Illinois, Rossi said.

Variants are of concern because they have been shown to be potentially more contagious and may have potential resistance to the vaccines. The Delta variant, first identified in India and confirmed in the United States in April, is believed to be more transmissible than previous strains of the virus.

Rossi said his goal in sharing sequencing information from time to time is to keep the public aware of the spreading variants.

Reditus tests nasal samples collected throughout the country for SARS-CoV-2 (COVID-19) using gold-standard PCR (polymerase chain reaction) testing. Reditus sequenced the samples using the Illumina NextSeq, which the laboratory began using earlier this year.

Reditus sequencing data is shared with the Illinois Department of Public Health, the U.S. Centers for Disease Control and Prevention and GISAID, a global initiative that provides access to genomic data of influenza viruses and COVID-19.

###

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory

REDITUS LABORATORIES REPORTS DELTA VARIANT IS CLEAR ‘DOMINANT STRAIN’August 2, 2021

FOR IMMEDIATE RELEASE: AUG. 2, 2021

PEKIN, IL – Reditus Laboratories in Pekin identified 347 additional cases of the B.1.617.2 variant — also known as the Indian double mutant variant or the Delta variant — during its sequencing run on July 29. This encompassed 95% of the entire sequenced positives.

Reditus had reported one case discovered via sequencing in May and two cases discovered through sequencing in June and 64 on its sequencing run on July 16. This means that Reditus has identified 414 cases of the Delta variant, said CEO Dr. Aaron Rossi.

Dr. Rossi on Monday said, “The Delta variant has clearly become the dominant strain out of our positive samples.”

The samples sequenced on July 29 were collected from July 2 through July 27. The 347 people were from throughout Illinois, including 30 positives from Bloomington-Normal, 23 from the Peoria area, 25 from the Rockford area, 29 from the Champaign-Urbana area and 100 from the Metro East St. Louis area.

During its sequencing run on July 29 at its lab in Pekin, Reditus tested 367 randomly selected positive COVID-19 samples. The 347 cases of the Delta variant represented 95% of the 367 samples. Among the other variants of concern was the Columbia variant known as the B.1.621.1. Three of those cases were identified during the sequencing run.

Variants are of concern because they have shown to be potentially more contagious and may have potential resistance to the vaccines. The Delta variant, first identified in India and confirmed in the United States in April, is believed to be more transmissible than previous strains of the virus.

Rossi said his goal in sharing sequencing information from time to time is simply to keep the public aware of the spreading variants.

Reditus tests nasal samples collected throughout the country for SARS-CoV-2 (COVID-19) using gold-standard PCR (polymerase chain reaction) testing. Reditus sequenced the 364 samples using the Illumina NextSeq, which the laboratory began using earlier this year.

Reditus sequencing data is shared with the Illinois Department of Public Health, the U.S. Centers for Disease Control and Prevention and GISAID, a global initiative that provides access to genomic data of influenza viruses and COVID-19.

###

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory Improvement Amendments (CLIA) program. Additional information is at www.redituslabs.com, as well as on Facebook at Reditus Laboratories and Twitter @ReditusLabs.

McLEAN COUNTY COVID TESTING SITE TO REMAIN OPEN AFTER JULY 31July 29, 2021

FOR IMMEDIATE RELEASE: JULY 29, 2021

PEKIN, IL – On July 28, ten out of 127 individuals tested positive for SARS-CoV2 (COVID-19) at the McLean County Fairgrounds testing site.

The COVID-19 testing site at the McLean County Fairgrounds was scheduled to close at 5 p.m. July 31 due to a decrease in testing. However, due to the increased SARS-CoV2 (COVID-19) positivity rate and significant concerns surrounding the Delta variant, the Illinois Department of Public Health has decided that community-based testing sites, including the site at the McLean County Fairgrounds, will remain open.

Reditus Laboratories has operated the site at 1106 Interstate Drive, Bloomington, for IDPH since May 2020.
Testing will continue, for now, at the site, 9 a.m. to 5 p.m. Monday, Wednesday, Friday and Saturday, said Dr. Aaron Rossi, CEO of Reditus Laboratories.

“We are, however, evaluating a potential location change in McLean County due to cost and disruption of our processes as more events are taking place at the fairgrounds,” Rossi said Thursday. “We will certainly make the public aware of any location change.”

During the site’s busiest time in fall 2020, nearly 1,300 people were tested per day. During the past two months, the site averaged about 30 people tested per day, Rossi said.

###

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory Improvement Amendments (CLIA) program. Additional information is at www.redituslabs.com, as well as on Facebook at Reditus Laboratories and Twitter @ReditusLabs.

REDITUS LABORATORIES REPORTS ‘SUBSTANTIAL’ INCREASE IN DELTA VARIANT CASES – July 21, 2021

FOR IMMEDIATE RELEASE, JULY 21

PEKIN, IL – Reditus Laboratories in Pekin identified 64 additional cases of the B.1.617.2 variant — also known as the Indian double mutant variant or the Delta variant — during its sequencing run on July 16.

Reditus had reported one case discovered via sequencing in May and two cases discovered through sequencing in June, meaning that Reditus has identified 67 cases of the Delta variant, said CEO Dr. Aaron Rossi.

Rossi on Wednesday called the increase “substantial.”

The samples sequenced on July 16 were collected from June 4 through July 7. The 64 people were from throughout Illinois, including several from Central Illinois and, specifically, 18 from the Peoria and Bloomington-Normal areas, Rossi said.

During its sequencing run on July 16 at its lab in Pekin, Reditus tested 364 randomly selected positive COVID-19 samples. The 64 cases of the Delta variant represented 18% of the 364 samples. Among other variants identified were 154 cases of the B.1.1.7 lineage, better known as the UK (United Kingdom) variant), representing 42% of the samples, and 107 cases of the P.1 (Brazilian) variant, representing 29% of the samples, Rossi said. Small numbers of other variants also were identified.

Variants are of concern because they are potentially more contagious and may have potential resistance to the vaccines. The Delta variant, first identified in India and confirmed in the United States in April, is believed to be more transmissible than previous strains of the virus.

Rossi said his goal in sharing sequencing information from time to time is simply to keep the public aware of the spreading variants.

Reditus tests nasal samples collected throughout the country for SARS-CoV-2 (COVID-19) using gold-standard PCR (polymerase chain reaction) testing. Reditus sequenced the 364 samples using the Illumina NextSeq, which the laboratory began using earlier this year.

Reditus sequencing data is shared with the Illinois Department of Public Health, the U.S. Centers for Disease Control and Prevention and GISAID, a global initiative that provides access to genomic data of influenza viruses and COVID-19.

###

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory Improvement Amendments (CLIA) program. Additional information is at www.redituslabs.com, as well as on Facebook at Reditus Laboratories and Twitter @ReditusLabs.

McLEAN COUNTY COVID TESTING SITE TO CLOSE AFTER JULY 31 – June 29, 2021

For Immediate Release: June 29, 2021

McLEAN COUNTY COVID TESTING SITE TO CLOSE AFTER JULY 31

PEKIN, IL – The COVID-19 testing site at the McLean County Fairgrounds will close indefinitely at 5 p.m. July 31.
Until then, the site, 1106 Interstate Drive, Bloomington, will remain open 9 a.m. to 5 p.m. Monday, Wednesday, Friday and Saturday, said Dr. Aaron Rossi, CEO of Reditus Laboratories, which has operated the testing site for the Illinois Department of Public Health since May of 2020.

“The state has decided, with the decreased testing numbers and site utilization, that Bloomington will be closing its site indefinitely, effective July 31, 2021,” Rossi said. “At this present time, the site will still be available to the public on the current schedule.”

The site averages about 60 people per day. During its busiest time in fall 2020, nearly 1,300 people were tested per day.

Reditus would like to thank McLean County and the McLean County Fairgrounds for the opportunity to serve the community.

#

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory Improvement Amendments (CLIA) program. Additional information is at www.redituslabs.com, as well as on Facebook at Reditus Laboratories and Twitter @ReditusLabs.

REDITUS, ROSSI, RECOGNIZED BY STATEJune 28, 2021

For Immediate Release: June 28, 2021

REDITUS, ROSSI, RECOGNIZED BY STATE


PEKIN – Reditus Laboratories and its CEO, Dr. Aaron Rossi, have been honored by the State of Illinois for contributions to Pekin and the entire state during the COVID-19 pandemic. State Rep. Mark Luft, R-Pekin, on Monday presented Rossi with two certifications of recognition from the Illinois General Assembly.


The first recognized Reditus for its contributions to Pekin and the State of Illinois for promoting safety and community support during the COVID-19 pandemic. Since April 2020, Reditus has performed more than 2.4 million tests for SARS-CoV-2 (COVID-19) using gold-standard PCR (polymerase chain reaction) testing.

The second certificate recognized Rossi for his dedication and efforts in creating jobs during the COVID-19 pandemic. Reditus, which opened in June 2019, has nearly 300 employees.


Luft recalled that after he became Pekin mayor, he met with Rossi to discuss Rossi’s plans for Reditus and how the company pivoted to provide COVID testing in spring 2020.

“I personally am aware of how much effort and work Aaron has put into this community and the surrounding communities for the last 15 months,” Luft said. “Thanks to Dr. Aaron Rossi and Reditus Laboratories, our community stayed safer.”


Luft said it was a good time in the COVID “journey” to recognize Rossi and Reditus. Rossi thanked Luft. “I always knew I had the support of the city and mayor,” Rossi said.

But Rossi said the credit goes to Reditus employees, including his wife, Molly Rossi, who also is Reditus vice president of clinical logistics.

“I am impressed every day with the dedication of our employees and their recognition that everything we do is for the patient,” Rossi said

#

Reditus Laboratories is a full-service laboratory company with a heavy focus on molecular diagnostics. Based in Pekin, Illinois, Reditus provides top-tier, accurate anatomical and clinical pathology services, including cytology, histology and molecular testing. Reditus is accredited by the College of American Pathologists (CAP) and is certified by the Clinical Laboratory Improvement Amendments (CLIA) program. Additional information is at www.redituslabs.com, as well as on Facebook at Reditus Laboratories and Twitter @ReditusLabs

Ways We Test

  • This field is for validation purposes and should be left unchanged.
Email Us

[email protected]

Come See Us

200 Enterprise Drive
Pekin, IL 61554

Give Us a Call

+1 (866) 736-0002

back to
top